Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., Jan. 20, 2011 (GLOBE NEWSWIRE) -- Amit N. Patel, MD, MS, associate professor of surgery at the University of Utah School of Medicine and national principal investigator in Aastrom's U.S. Phase 2 IMPACT-DCM clinical trial, and Sharon Watling, Pharm.D., Aastrom's vice president of
ANN ARBOR, Mich., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, today announced that it has been granted a U.S. patent which provides composition of matter
ANN ARBOR, Mich., Dec. 15, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has completed a public offering of 10,000,000 units at a
ANN ARBOR, Mich., Dec. 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it has priced a public offering of 10,000,000 units, with
ANN ARBOR, Mich., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that it is commencing a public offering of its common stock and
ANN ARBOR, Mich., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom will present data from an interim analysis of its Phase 2b RESTORE-CLI clinical trial at a VEITHsymposium™ non-CME satellite session. This event will include
Preparing for Phase 3 Critical Limb Ischemia Clinical Program Company to Present Phase 2b CLI Interim Data at a VEITHsymposium™ Satellite Session on November 18 at 1:00 p.m. (ET) ANN ARBOR, Mich., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast: What: Aastrom Biosciences, Inc., First Quarter Fiscal Year 2011 Investor Conference Call When: Monday, November 8, 2010 @ 9:30 am (ET)
ANN ARBOR, Mich., Oct. 27, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that Tim Mayleben, president and CEO, will present on behalf of the company
